Christopher Lisi, MD
Otolaryngology · New Hyde Park, NYNPI 1861767055
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $4,454 of the $6,565 with a category attached, or 67.8%. Ambu Inc. accounts for 62.0% of it on its own, with 14 other manufacturers making up the rest. Reporting peaked in 2022 at $3,664 and has fallen 84.5% since, to $570 in 2025.
Across 73 payments — averaging $89.94 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ambu Inc.$4K
- Inspire Medical Systems, Inc.$560
- Verathon Inc.$550
- Optinose US, Inc.$463
- Medtronic$229
- Intersect ENT, Inc.$128
- plus $561 from 9 others
What the payments were for
- Consulting fees$4,45468%
- Food & beverage$2,11232%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ambu Inc. | 14 | $4,074 |
| Inspire Medical Systems, Inc. | 9 | $560 |
| Verathon Inc. | 1 | $550 |
| Optinose US, Inc. | 19 | $463 |
| Medtronic(2 entities) | 4 | $229 |
| Intersect ENT, Inc. | 3 | $128 |
| GSK | 6 | $127 |
| Integra Lifesciences Corporation | 4 | $107 |
| Kerecis Limited | 2 | $89 |
| Stryker | 4 | $85 |
| Regeneron Healthcare Solutions, Inc. | 3 | $61 |
| Acclarent, Inc | 1 | $25 |
| Aerin Medical Inc. | 1 | $23 |
| Itamar Medical Inc | 1 | $22 |
| AstraZeneca | 1 | $21 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Bronchoscope$550
- Inspire$257
- Xhance$128
- PROPEL$100
How this compares
$6,565 in reported general payments places this provider in the 85th percentile of 701 otolaryngology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Fluticasone Propionate | 227 | $3,793 |
| Azelastine Hcl | 170 | $3,668 |
| Ofloxacin | 56 | $2,284 |
| Famotidine | 92 | $1,005 |
| Ipratropium Bromide | 46 | $959 |
| Omeprazole | 67 | $796 |
| Tobramycin-DexamethasoneTobramycin/Dexamethasone | 13 | $769 |
| Mupirocin | 17 | $428 |
| Pantoprazole Sodium | 26 | $251 |
| Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav | 13 | $136 |
Paid to pharmacies, not to this prescriber.
Other otolaryngology in New Hyde Park
- Moshe EphratNew Hyde Park$250K
- Robert KellmanSyracuse$2.5M
- Roheen RaithathaNew York$830K
- Nora PerkinsAlbany$300K
- Gavin SetzenAlbany$243K
- Habibullah JamalRye Brook$179K
- Albert JenFlushing$171K
- Dennis KrausNew York$159K
- Nitin BhatiaWhite Plains$120K
- Sveta KarelskyRochester$101K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.